Themis Medicare Analyst Review May 2026
- May 27, 2026
- Posted by: Kashish Aggarwal
- Category: News
This Themis Medicare analyst review for May 2026 covers all critical data investors need for THEMISMED at Rs 100.24. Themis Medicare is a pharmaceutical company focused on specialty therapeutics. This Themis Medicare analyst review analyses technical levels, business fundamentals, valuation, and key risks for THEMISMED through FY27.
Click Here – Get Free Investment Predictions
Themis Medicare Analyst Review: Company Snapshot May 2026
Themis Medicare manufactures specialty formulations for infectious diseases, critical care, and neurology under its own brand and contract manufacturing. The table below summarises key metrics for this Themis Medicare analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | THEMISMED |
| Sector | Pharmaceuticals – Specialty Drugs |
| CMP (May 2026) | Rs 100.24 |
| 52 Week High | Rs 120.28 |
| 52 Week Low | Rs 80.20 |
| Market Cap | Rs 500 Crore |
| Trailing P/E | 22x |
| Analyst Consensus Target | Rs 125.30 |
| Bull Case Target | Rs 155.37 |
| Bear Case Target | Rs 85.20 |
Analyst Insight: Themis Medicare Analyst Review for FY27
Associate Director Kunal Singla suggests watching Themis Medicare closely in May 2026. At Rs 100.24, Kunal Singla flags Pharmaceuticals – Specialty Drugs sector dynamics as the key driver for THEMISMED’s price action. Support is near Rs 81.80 and resistance near Rs 106.25. Kunal Singla’s perspective in this Themis Medicare analyst review is not a buy recommendation.
Technical Analysis in This Themis Medicare Analyst Review
This Themis Medicare analyst review places THEMISMED at Rs 100.24 within its 52-week band of Rs 80.20 to Rs 120.28. The 14-day RSI, MACD signal, and volume profile are key technical inputs when evaluating THEMISMED.
The Themis Medicare analyst review identifies support in the Rs 81.80 to Rs 95.23 range and resistance in the Rs 106.25 to Rs 112.77 zone. A sustained close above Rs 106.25 could signal momentum toward the analyst consensus target of Rs 125.30.
Screen the best stocks on the Univest Screener.
Support and Resistance in This Themis Medicare Analyst Review
- Support Zone: Rs 81.80 to Rs 95.23 – this Themis Medicare analyst review identifies this as a potential accumulation signal for THEMISMED.
- Resistance Zone: Rs 106.25 to Rs 112.77 – the Themis Medicare analyst review flags a close above Rs 106.25 as a positive signal for THEMISMED.
- Consensus Target: Rs 125.30 is the base-case target in this Themis Medicare analyst review.
Business Segments in This Themis Medicare Analyst Review
Specialty Pharma Formulations
This primary segment drives revenue and margin for Themis Medicare, supporting the earnings trajectory toward Rs 125.30 in this Themis Medicare analyst review.
Critical Care and Infectious Disease Drugs
This segment adds meaningful scale to Themis Medicare’s model and is a key EPS contributor through FY27 as identified in this Themis Medicare analyst review.
Contract Manufacturing
This growth frontier is a potential re-rating catalyst for THEMISMED and a key element of this Themis Medicare analyst review.
Valuation: Themis Medicare Analyst Review Bull Bear Base Case
At Rs 100.24 and P/E of 22x, this Themis Medicare analyst review sets three scenarios: bull case Rs 155.37, base case Rs 125.30, and bear case Rs 85.20.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 155.37 | Strong FY27 delivery and Pharmaceuticals – Specialty Drugs re-rating |
| Base Case | Rs 125.30 | Moderate growth per analyst consensus in this Themis Medicare analyst review |
| Bear Case | Rs 85.20 | Earnings miss or macro headwinds for THEMISMED |
FY27 Outlook in This Themis Medicare Analyst Review
This Themis Medicare analyst review for FY27 is constructive provided THEMISMED delivers on earnings expectations. Q1 FY27 results will be the first checkpoint. Investors should monitor Pharmaceuticals – Specialty Drugs indicators, RBI policy, and FII flow trends.
Key Risks in This Themis Medicare Analyst Review
This Themis Medicare analyst review identifies four key risks for THEMISMED: macro slowdown, input cost pressure, FII selling, and Q1 FY27 earnings disappointment.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Themis Medicare Analyst Review Verdict May 2026
This Themis Medicare analyst review concludes that THEMISMED at Rs 100.24 presents a defined risk-reward with consensus target Rs 125.30. The 52-week range of Rs 80.20 to Rs 120.28 provides further context. Use this Themis Medicare analyst review as a research reference and consult a SEBI-registered advisor before investing in THEMISMED.
FAQs: Themis Medicare Analyst Review 2026
What is the analyst target for Themis Medicare in 2026?
The Themis Medicare analyst review consensus target is Rs 125.30, bull case Rs 155.37, bear case Rs 85.20.
Is Themis Medicare a good buy at Rs 100.24?
At Rs 100.24 with PE 22x and target Rs 125.30, this Themis Medicare analyst review is constructive for 12-month investors. Consult a SEBI-registered advisor before acting on this Themis Medicare analyst review.
What is the 52-week high and low of Themis Medicare?
52-week high is Rs 120.28 and 52-week low is Rs 80.20. This Themis Medicare analyst review contextualises THEMISMED at Rs 100.24 within this range.
What are the key risks for Themis Medicare?
Key risks in this Themis Medicare analyst review: macro slowdown, input cost pressure, FII selling, and competitive pressure in the Pharmaceuticals – Specialty Drugs sector.
Where can I track live data for Themis Medicare?
Track Themis Medicare’s live price on the Univest Screener to complement this Themis Medicare analyst review with real-time data.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
